Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

IVBM Phoenix logo | Image: AJMC
Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

May 19th 2025

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com
The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

May 17th 2025

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

April 25th 2025

Health equity concept | image credit: VectorMine - stock.adobe.com
Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

April 7th 2025

Targeting GPRC5D Holds Promise in Multiple Myeloma
Targeting GPRC5D Holds Promise in Multiple Myeloma

April 3rd 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Continuing Medical Education
View All
June 7th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
June 7th 2025

Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy

1.5 Credits / Oncology, Hematology, Hematologic Cancer
June 7th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
June 7th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer

More News

MAIA Study and Subgroup Analysis
December 21st 2022

MAIA Study and Subgroup Analysis

Ryan Haumschild, PharmD, MS, MBA, leads a panel in a conversation reviewing the MAIA study.
Front-line Treatment Management for Patients with Multiple Myeloma (MM)
December 21st 2022

Front-line Treatment Management for Patients with Multiple Myeloma (MM)

Key opinion leaders open a discussion surrounding the current treatment landscape of multiple myeloma (MM).
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care
December 17th 2022

Dr Hossein Kazemi Discusses De-escalating Treatment Tools for Patients With Multiple Myeloma

Pearl Steinzor
M. Hossein Kazemi, MD, medical oncologist and hematologist, Astera Cancer Care, identifies key tools in de-escalating treatment for patients with multiple myeloma.
Astera Cancer Care Shows How Community Oncology Can Innovate Both in the Clinic and in Contracting
December 2nd 2022

Astera Cancer Care Shows How Community Oncology Can Innovate Both in the Clinic and in Contracting

Mary Caffrey
Coverage from the Institute for Value-Based Medicine® session with Astera Cancer Care in Edison, New Jersey, held November 3, 2022.
Image of nurse administering palliative care
December 1st 2022

End-of-Life Care in Multiple Myeloma Still Requires Fine-tuning, Despite Improvements

Rose McNulty
Thirteen years of population-based data highlight substantial rates of aggressive end-of-life care and disparities in care within a publicly funded health care system in Ontario, Canada.
Graphic representing COVID-19 risk
November 29th 2022

Predictors of Severe COVID-19 Infection, Mortality in Patients With MM, AL Identified

Jaime Rosenberg
Their findings, say the researchers, offer useful insights into the outcomes and risks of severe disease and mortality in patients who have multiple myeloma (MM) or amyloidosis (AL) with underlying monoclonal gammopathy who contract COVID-19.
Image of a reengineered cell
November 18th 2022

CAR T-Cell Therapy Can Work as Salvage Treatment in Relapsed MM Following BCMA-Directed CAR T

Jared Kaltwasser
New data show patients treated with chimeric antigen receptor (CAR) T-cell therapy as salvage therapy tended to have meaningful results despite treatment failure following B-cell maturation antigen (BCMA) CAR T.
Image of an electronic medical record
November 14th 2022

EHR Data Show MM Treatment Burden Higher Than Chronic Lymphoid Leukemia

Jared Kaltwasser
This new study shows how using electronic health record (EHR) data can objectively quantify patient treatment burden among individuals who have multiple myeloma (MM) compared with patient-reported outcomes, which can be subject to recall bias.
Joseph Alvarnas, MD.
November 12th 2022

Dr Joseph Alvarnas: Cancer Care Equity Act Meets the Needs of Patients With Advanced Disease

Matthew Gavidia
Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke on how the California Cancer Care Equity Act will allow oncologists to escalate the care of patients with advanced cancers toward established centers that can better meet their needs, as well as implications from the decision to exclude genomic testing coverage in the bill.
graphic depicting time
November 12th 2022

Shorter Time to Treatment Is Associated With Worse OS in Multiple Myeloma, Study Finds

Rose McNulty
The study highlights a need for further research into potential contributors, including the possibility that sicker patients may receive more prompt treatment.
Bhavesh Shah
November 7th 2022

Bhavesh Shah Discusses Expanding Access for BCMA Bispecific Antibody

Hayden E. Klein
Bhavesh Shah, RPh, BCOP, chief pharmacy officer and director of specialty and hematology/oncology pharmacy at Boston Medical Center, talks about what oncology agents in the pipeline he hopes to see become available.
FDA approved
October 26th 2022

FDA Approves First Bispecific Antibody, Teclistamab, for R/R Multiple Myeloma

Christina Mattina
The FDA’s approval of teclistamab for relapsed/refractory (R/R) multiple myeloma makes it the first bispecific T-cell engager antibody to enter the treatment landscape.
image of smartphone
October 20th 2022

Can Digital Exercise Benefit Patients With Multiple Myeloma?

Mary Caffrey
Although exercise during cancer treatment is encouraged, multiple myeloma can present special challenges, since there is an increased risk of bone fractures, pain, and other deformities.
Multiple myeloma
October 14th 2022

Model Predicts Early Disease Progression for Patients With Multiple Myeloma

Rose McNulty
The model was found to be predictive and may help identify patients with multiple myeloma at a high risk of early disease progression.
Multiple myeloma
October 14th 2022

Study Identifies Lenalidomide-Carfilzomib as Best Maintenance Treatment Option in MM

Rose McNulty
Within a selection of therapies showing efficacy over a placebo, lenalidomide-carfilzomib was a standout against the rest of the group.
PCPs Can Pave Way to Faster Diagnosis of Multiple Myeloma
October 10th 2022

PCPs Can Pave Way to Faster Diagnosis of Multiple Myeloma

Jaime Rosenberg
Researchers highlighted the opportunities primary care providers (PCPs) have to promote favorable outcomes through prompt diagnosis as well as help reduce racial disparities in multiple myeloma.
MM survivor
October 6th 2022

Study Evaluates Factors Related to HRQOL in Multiple Myeloma

Mary Caffrey
Regular assessments of patient-reported outcomes (PROs) are important to deliver the best clinical care, including the monitoring health-related quality of life (HRQOL), researchers reported.
Ajay Nooka, MD, MPH, FACP, Winship Cancer Institute
September 16th 2022

Dr Ajay Nooka Discusses Cost Savings and QOL Benefits of MRD-Directed Treatment Decisions

Laura Joszt, MA Skylar Jeremias
Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
picture of blood cells
September 12th 2022

CAR T-Cell Therapy a Story of Opportunities and Challenges in MM

Jared Kaltwasser
Chimeric antigen receptor (CAR) T-cell therapies may help patients with otherwise refractory cases of multiple myeloma, but patients must overcome significant hurdles to access the therapy.
Could CAR-NK Cells Using Cord Blood Offer a Treatment for Multiple Myeloma?
September 9th 2022

Could CAR-NK Cells Using Cord Blood Offer a Treatment for Multiple Myeloma?

Mary Caffrey
For several years, investigators have examined the potential for allogenic natural killer (NK) cells as an alternative for “off-the-shelf” chimeric antigen receptor (CAR) treatments. New study results presented at the International Myeloma Society (IMS) meeting showed CD38 CAR-NK cells significantly reduced the tumor burden—and improved survival
Ajay Nooka, MD, MPH, FACP
September 5th 2022

How Should MRD Results Be Used? Experts Don’t Necessarily Agree, Dr Ajay Nooka Says

Laura Joszt, MA Skylar Jeremias
Everyone agrees that minimal residual disease (MRD) is the best prognostic tool for multiple myeloma, but there is disagreement on how to use the MRD results, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Ajay Nooka, MD, MPH, FACP
September 2nd 2022

Dr Ajay Nooka Discusses Use of MRD Testing in Multiple Myeloma at Emory

Laura Joszt, MA Skylar Jeremias
Minimal residual disease (MRD) testing is used to understand the depth of response, but currently the data at Emory are not used to make treatment decisions, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Final Analysis of Phase 2 GRIFFIN Shows Daratumumab Improves PFS After 4 Years
August 27th 2022

Final Analysis of Phase 2 GRIFFIN Shows Daratumumab Improves PFS After 4 Years

Mary Caffrey
Patients receiving the quadruplet therapy have continued to show improved responses and higher rates of minimal residual disease (MRD) negativity.
Image of different skin tones
August 19th 2022

Daratumumab Access Differences Highlight Potential Racial Disparities in MM Care

Maggie L. Shaw
This retrospective chart review investigated outcomes among patients who are White or Black on a daratumumab regimen for multiple myeloma (MM).
Patient filling out form
August 12th 2022

QOL Tool Valuable in Identifying Patients’ Chief Concerns

Julia Bonavitacola
A tool used to identify primary concerns of patients was helpful in identifying main worries about time, as it related to quality of life (QOL), and held value for patients and clinicians.
Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS
August 10th 2022

Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS

Mary Caffrey
Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.
x-ray of lungs
August 6th 2022

Rare MM Case Underscores Need to Consider Differential Diagnoses

Maggie L. Shaw
In this case report, a 50-year-old female patient, with a family history of lung cancer, received a diagnosis of multiple myeloma (MM) following presentation with an apical lung mass.
Image of lab research
August 4th 2022

NGF-Based MRD Assessment Demonstrates Potential to Predict MM Disease Progression

Maggie L. Shaw
Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.
myeloma cells
July 28th 2022

Early Use of Novel Therapies in Multiple Myeloma Could Target Bone Marrow Microenvironment

Mary Caffrey
Authors explained how multiple myeloma emerges from earlier clinical phases and the tumor’s microenvironment in the early course of the disease plays a critical role in the survival of myeloma cells.
With Multiple Myeloma, Caregivers May See More Mental Health Effects Than Patients
July 18th 2022

With Multiple Myeloma, Caregivers May See More Mental Health Effects Than Patients

Mary Caffrey
A study in Blood Advances highlights the toll that a terminal diagnosis can have on everyone around a patient.
<1
...
34567891011>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo